Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Effect of mosapride 30mg/day on the small bowel and colon transit time in patients with chronic constipation or constipated irritable bowel syndrome.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Mosapride

Criteria

Inclusion Criteria:

• Functional constipation or constipated irritable bowel syndrome patients according to Rome III criteria

Exclusion Criteria:

• Intolerable or hypersensitive to mosapride

• Known Parkinson's ds

• Cardio- or cerebrovascular disease within 3 months

• Malignancy requiring surgery or chemotherapy or radiation within 5 years

• History of GI surgeries except hernia repair, appendectomy, primary closure due to perforation

• Refractory diabetes mellitus/hypertension/thyroid diseases

• Symptomatic heart failure, renal failure, arrhythmia